Search Results

• • 3 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Therapeutic targets and signaling pathways of active components of QiLing decoction against castration-resistant prostate cancer based on network pharmacology.

  Authors:Hongwen Cao, Dan Wang, Renjie Gao, Chenggong Li, Yigeng Feng, and Lei ChenFrom:PeerJ (Vol. 10) Peer-Reviewed

  June 27, 20226,148 words Article 1430LQiLing decoction (QLD) is a traditional Chinese medicine compound. This study aims to explore the therapeutic effect of QLD in castration-resistant prostate cancer (CRPC) and its potential bio-targets. A total of 51...

• Expression of MUS81 Mediates the Sensitivity of Castration-Resistant Prostate Cancer to Olaparib.

  Authors:Lifeng Gong, Yu Tang, Li Jiang, Wei Tang, and Shengjun LuoFrom:Journal of Immunology Research (Vol. 2022) Peer-Reviewed

  July 21, 20225,902 words Article 1480LThis project attempts to clarify the expression of MUS81 in castration-resistant prostate cancer (CRPC) and the effect on drug sensitivity to Olaparib. We collected clinical surgical samples of patients who were...

• Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.

  Authors:Jai-Shin Liu, Wei-Kai Fang, Shan-Min Yang, Meng-Chen Wu, Tsan-Jan Chen, Chih-Ming Chen, et al.From:Journal of Biomedical Science (Vol. 29, Issue 1) Peer-Reviewed

  May 9, 20226,455 words Article 1370LBackground Castration-resistant prostate cancer (CRPC) with sustained androgen receptor (AR) signaling remains a critical clinical challenge, despite androgen depletion therapy. The Jumonji C-containing histone lysine...